ValÃ©rie Vingtdeux

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9360053/publications.pdf

Version: 2024-02-01

50 papers	4,737 citations	172457 29 h-index	189892 50 g-index
60 all docs	60 docs citations	60 times ranked	9089 citing authors

#	Article	IF	Citations
1	AMP-activated Protein Kinase Signaling Activation by Resveratrol Modulates Amyloid-Î² Peptide Metabolism. Journal of Biological Chemistry, 2010, 285, 9100-9113.	3.4	560
2	CALHM1 ion channel mediates purinergic neurotransmission of sweet, bitter and umami tastes. Nature, 2013, 495, 223-226.	27.8	405
3	Massive CA1/2 Neuronal Loss with Intraneuronal and N-Terminal Truncated AÎ²42 Accumulation in a Novel Alzheimer Transgenic Model. American Journal of Pathology, 2004, 165, 1289-1300.	3.8	375
4	Resveratrol mitigates lipopolysaccharideâ€•and AÎ²â€•mediated microglial inflammation by inhibiting the TLR4/NFâ€ÎºB/STAT signaling cascade. Journal of Neurochemistry, 2012, 120, 461-472.	3.9	363
5	A Polymorphism in CALHM1 Influences Ca2+ Homeostasis, AÎ² Levels, and Alzheimer's Disease Risk. Cell, 2008, 133, 1149-1161.	28.9	310
6	Calcium signaling in neurodegeneration. Molecular Neurodegeneration, 2009, 4, 20.	10.8	258
7	AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimerâ€™s disease and other tauopathies. Acta Neuropathologica, 2011, 121, 337-349.	7.7	247
8	Novel synthetic smallâ€•molecule activators of AMPK as enhancers of autophagy and amyloidâ€Î² peptide degradation. FASEB Journal, 2011, 25, 219-231.	0.5	209
9	Therapeutic potential of resveratrol in Alzheimer's disease. BMC Neuroscience, 2008, 9, S6.	1.9	178
10	Alkalizing Drugs Induce Accumulation of Amyloid Precursor Protein By-products in Luminal Vesicles of Multivesicular Bodies. Journal of Biological Chemistry, 2007, 282, 18197-18205.	3.4	176
11	Inhibition of AMP-Activated Protein Kinase Signaling Alleviates Impairments in Hippocampal Synaptic Plasticity Induced by Amyloid Î². Journal of Neuroscience, 2014, 34, 12230-12238.	3.6	143
12	Calcium homeostasis modulator 1 (CALHM1) is the pore-forming subunit of an ion channel that mediates extracellular Ca ²⁺ regulation of neuronal excitability. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E1963-71.	7.1	132
13	AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo. Scientific Reports, 2016, 6, 26758.	3.3	95
14	Potential Contribution of Exosomes to the Prion-Like Propagation of Lesions in Alzheimerâ€™s Disease. Frontiers in Physiology, 2012, 3, 229.	2.8	93
15	Down-Regulation of the Met Receptor Tyrosine Kinase by Presenilin-dependent Regulated Intramembrane Proteolysis. Molecular Biology of the Cell, 2009, 20, 2495-2507.	2.1	92
16	Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism. Neurobiology of Disease, 2005, 20, 625-637.	4.4	82
17	Intracellular pH regulates amyloid precursor protein intracellular domain accumulation. Neurobiology of Disease, 2007, 25, 686-696.	4.4	78
18	Identification and biology of Î±â€•secretase. Journal of Neurochemistry, 2012, 120, 34-45.	3.9	77

#	Article	IF	Citations
19	Small-Molecule Activators of AMP-Activated Protein Kinase (AMPK), RSVA314 and RSVA405, Inhibit Adipogenesis. Molecular Medicine, 2011, 17, 1022-1030.	4.4	75
20	AMP-Activated Protein Kinase Is Essential for the Maintenance of Energy Levels during Synaptic Activation. IScience, 2018, 9, 1-13.	4.1	59
21	CB2 Receptor Deficiency Increases Amyloid Pathology and Alters Tau Processing in a Transgenic Mouse Model of Alzheimerâ€™s Disease. Molecular Medicine, 2014, 20, 29-36.	4.4	55
22	Neuronal AMP-activated protein kinase hyper-activation induces synaptic loss by an autophagy-mediated process. Cell Death and Disease, 2019, 10, 221.	6.3	54
23	Overexpression of MBNL1 fetal isoforms and modified splicing of Tau in the DM1 brain: Two individual consequences of CUG trinucleotide repeats. Experimental Neurology, 2008, 210, 467-478.	4.1	47
24	AMPK in Neurodegenerative Diseases. Exs, 2016, 107, 153-177.	1.4	38
25	CALHM1 controls the Ca2+-dependent MEK, ERK, RSK and MSK signaling cascade in neurons. Journal of Cell Science, 2013, 126, 1199-1206.	2.0	35
26	Chloroquine and Chloroquinoline Derivatives as Models for the Design of Modulators of Amyloid Peptide Precursor Metabolism. ACS Chemical Neuroscience, 2015, 6, 559-569.	3.5	35
27	CALHM1 ion channel elicits amyloid-Î² clearance by insulin-degrading enzyme in cell lines and in vivo in the mouse brain. Journal of Cell Science, 2015, 128, 2330-2338.	2.0	32
28	Epstein-Barr Virus Protein EB2 Contains an N-Terminal Transferable Nuclear Export Signal That Promotes Nucleocytoplasmic Export by Directly Binding TAP/NXF1. Journal of Virology, 2009, 83, 12759-12768.	3.4	31
29	AMPK in Neurodegenerative Diseases: Implications and Therapeutic Perspectives. Current Drug Targets, 2016, 17, 890-907.	2.1	31
30	Protein Kinase CK2 Phosphorylation of EB2 Regulates Its Function in the Production of Epstein-Barr Virus Infectious Viral Particles. Journal of Virology, 2007, 81, 11850-11860.	3.4	30
31	CALHM1 deficiency impairs cerebral neuron activity and memory flexibility in mice. Scientific Reports, 2016, 6, 24250.	3.3	30
32	Identification of potent smallâ€molecule inhibitors of <scp>STAT</scp>3 with antiâ€inflammatory properties in <scp>RAW</scp>Â264.7 macrophages. FEBS Journal, 2012, 279, 3791-3799.	4.7	29
33	AMP-activated Protein Kinase Controls Immediate Early Genes Expression Following Synaptic Activation Through the PKA/CREB Pathway. International Journal of Molecular Sciences, 2018, 19, 3716.	4.1	29
34	CALHM1 P86L Polymorphism Modulates CSF AÎ² Levels in Cognitively Healthy Individuals at Risk for Alzheimerâ€™s Disease. Molecular Medicine, 2011, 17, 974-979.	4.4	26
35	Response: CALHM1 Association with Alzheimer's Disease Risk. Cell, 2008, 135, 994-996.	28.9	25
36	Contribution of the Endosomal-Lysosomal and Proteasomal Systems in Amyloid-Î² Precursor Protein Derived Fragments Processing. Frontiers in Cellular Neuroscience, 2018, 12, 435.	3.7	24

#	Article	IF	Citations
37	CB2 Receptor Deficiency Increases Amyloid Pathology and Alters Tau Processing in a Transgenic Mouse Model of Alzheimerâ€™s Disease. Molecular Medicine, 2013, 19, 29-36.	4.4	22
38	New piperazine multi-effect drugs prevent neurofibrillary degeneration and amyloid deposition, and preserve memory in animal models of Alzheimer's disease. Neurobiology of Disease, 2019, 129, 217-233.	4.4	21
39	The neuroprotective activity of heat-treated human platelet lysate biomaterials manufactured from outdated pathogen-reduced (amotosalen/UVA) platelet concentrates. Journal of Biomedical Science, 2019, 26, 89.	7.0	20
40	Recovery of brain biomarkers following peroxisome proliferator-activated receptor agonist neuroprotective treatment before ischemic stroke. Proteome Science, 2014, 12, 24.	1.7	17
41	Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarker. Neurobiology of Aging, 2013, 34, 757-769.	3.1	16
42	A phenotypic approach to the discovery of compounds that promote non-amyloidogenic processing of the amyloid precursor protein: Toward a new profile of indirect Î²-secretase inhibitors. European Journal of Medicinal Chemistry, 2018, 159, 104-125.	5.5	16
43	Growth arrest-specific 1 binds to and controls the maturation and processing of the amyloid-Î² precursor protein. Human Molecular Genetics, 2011, 20, 2026-2036.	2.9	15
44	Postnatal neurodevelopmental expression and glutamate-dependent regulation of the ZNF804A rodent homologue. Schizophrenia Research, 2015, 168, 402-410.	2.0	12
45	Effect of the CALHM1 G330D and R154H Human Variants on the Control of Cytosolic Ca2+ and AÎ² Levels. PLoS ONE, 2014, 9, e112484.	2.5	11
46	A Modification-Specific Peptide-Based immunization Approach Using CRM197 Carrier Protein: Development of a Selective Vaccine Against Pyroglutamate AÎ² Peptides. Molecular Medicine, 2016, 22, 841-849.	4.4	7
47	Study of AMPK-Regulated Metabolic Fluxes in Neurons Using the Seahorse XFe Analyzer. Methods in Molecular Biology, 2018, 1732, 289-305.	0.9	7
48	Gas1 Interferes with AÎ²PP Trafficking by Facilitating the Accumulation of Immature AÎ²PP in Endoplasmic Reticulum-Associated Raft Subdomains. Journal of Alzheimer's Disease, 2012, 28, 127-135.	2.6	2
49	Letter to the Editor on â€œInvolvement of AMP-activated-protein-kinase (AMPK) in neuronal amyloidogenesisâ€• Biochemical and Biophysical Research Communications, 2010, 400, 452.	2.1	1
50	Contribution of Multivesicular Bodies to the Prion-Like Propagation of Lesions in Alzheimerâ€™s Disease. , 2011, , .		0